Rates of clinically apparent heparin-induced thrombocytopenia for unfractionated heparin vs. low molecular weight heparin in non-surgical patients are low and similar.
Rates of clinically apparent heparin-induced thrombocytopenia for unfractionated heparin vs. low molecular weight heparin in non-surgical patients are low and similar.
复制标题
DOI：
10.1186/1477-9560-3-4
复制
发表时间：
2005-04-04
影响因子：
3.1
通讯作者：
Gerber J
中科院分区：
文献类型：
--
作者：
Locke CF;Dooley J;Gerber J
随着低分子量肝素（LMWH）越来越多地用于治疗和预防静脉血栓栓塞（VTE），提供与普通肝素（UFH）关于肝素诱导的血小板减少症（HIT）发生率的循证比较非常重要。这种比较对于临床决策和成本建模至关重要。在本文中，我们回顾了有关非手术（医疗）患者的数据。我们的结论是，当前文献中缺乏对 HIT 的统一评估和标准化测试，无法对 UFH 与 LMWH 治疗或预防非手术患者 VTE 中 HIT 的相对风险做出可靠估计。然而，目前的数据表明，接受 LMWH 或 UFH 的非手术患者发生血小板减少症和 HIT 的风险较低且相似。
With the growing use of low-molecular-weight heparins (LMWH) for the treatment and prevention of venous thromboembolism (VTE), it is important to provide an evidence-based comparison with unfractionated heparin (UFH) concerning rates of heparin-induced thrombocytopenia (HIT). Such comparisons are essential in clinical decision-making and cost-modeling. In this paper we review data regarding non-surgical (medical) patients. We conclude that the lack of uniform evaluation and standardized testing for HIT in the current literature precludes making a reliable estimate of the relative risk of HIT in UFH vs. LMWH in either the treatment or prevention of VTE in non-surgical patients. However, current data suggest that the risk of thrombocytopenia and HIT is low and similar for non-surgical patients who receive either LMWH or UFH.